SCH 486757

Drug Profile

SCH 486757

Alternative Names: SCH-486757

Latest Information Update: 12 Jun 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Class Antitussives
  • Mechanism of Action Nociceptin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cough

Most Recent Events

  • 01 Jan 2013 Discontinued - Phase-II for Cough in United Kingdom (PO)
  • 04 Nov 2009 Schering-Plough has been acquired and merged into Merck & Co
  • 30 Nov 2007 Schering-Plough initiates enrolment in a phase II trial for Cough in the UK (NCT00506987)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top